You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Androgen receptor

Showing 26 - 50 of 8,225
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Prostatic Tumor Trial (AAA617, AAA517, Piflufolastat F 18)

Not yet recruiting
  • Prostatic Neoplasm
  • (no location specified)
Apr 27, 2023

PCOS, Polycystic Ovary Syndrome Trial in Charlottesville (Micronized progesterone, Placebo, Flutamide)

Recruiting
  • PCOS
  • Polycystic Ovary Syndrome
  • Micronized progesterone
  • +3 more
  • Charlottesville, Virginia
    University of Virginia
May 16, 2022

Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer Trial

Not yet recruiting
  • Hormone Receptor-positive Breast Cancer
  • +2 more
  • Nashville, Tennessee
    Sarah Cannon Research Institute
Oct 5, 2022

Metastatic Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Trial in United States (Darolutamide, Enzalutamide)

Recruiting
  • Metastatic Prostate Cancer
  • +3 more
  • San Diego, California
  • +11 more
Nov 28, 2022

Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative Trial in United States (Biomarker Analysis,

Active, not recruiting
Has Results
  • Estrogen Receptor Negative
  • +6 more
  • Biomarker Analysis
  • +3 more
  • Birmingham, Alabama
  • +8 more
Feb 3, 2022

Breast Cancer, Metastasis Trial in New York (Abemaciclib, Bicalutamide)

Recruiting
  • Breast Cancer
  • Metastasis
  • New York, New York
  • +2 more
Oct 14, 2021

Advanced Epithelial Ovarian, Recurrent Epithelial Ovarian, Fallopian Tube Trial in United States (Enzalutamide)

Completed
  • Advanced Epithelial Ovarian
  • +3 more
  • Basking Ridge, New Jersey
  • +5 more
Mar 4, 2022

Prostate Cancer, Stereotactic Body Radiation Therapy Trial (SBRT, STANDARD OF CARE)

Not yet recruiting
  • Prostate Cancer
  • Stereotactic Body Radiation Therapy
  • SBRT
  • STANDARD OF CARE
  • (no location specified)
Jan 25, 2022

Metastatic Castration-resistant Prostate Cancer Trial (ONC-392, lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • ONC-392
  • lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV infusion, Q6W for up to 6 doses.
  • (no location specified)
Dec 27, 2022

Hyperandrogenism, Polycystic Ovary Syndrome, Puberty Trial in Charlottesville (Micronized progesterone, Spironolactone, Placebo)

Recruiting
  • Hyperandrogenism
  • +2 more
  • Micronized progesterone
  • +2 more
  • Charlottesville, Virginia
    University of Virginia Clinical Research Unit
May 16, 2022

Prostate Cancer, Prostate Adenocarcinoma Trial (drug, other, procedure)

Not yet recruiting
  • Prostate Cancer
  • Prostate Adenocarcinoma
  • (no location specified)
Feb 2, 2023

In-vitro Diagnostic Test to Predict COVID-19 Mortality and

Recruiting
  • SARS-CoV 2
  • +5 more
  • CAG length <22
  • CAG length >=22
  • Madrid, Spain
    Hospital Universitario Ramon y Cajal
Feb 17, 2022

Metastatic Hormone-sensitive Prostate Cancer Trial in United States (Darolutamide (BAY1841788, Nubeqa), ADT)

Recruiting
  • Metastatic Hormone-sensitive Prostate Cancer
  • Darolutamide (BAY1841788, Nubeqa)
  • ADT
  • Homewood, Alabama
  • +11 more
Jan 13, 2023

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on

Terminated
  • Castration-Resistant Prostate Carcinoma
  • +4 more
  • Computed Tomography
  • +2 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Sep 19, 2022

Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma Trial

Not yet recruiting
  • Locally Advanced Salivary Gland Carcinoma
  • +3 more
  • Biopsy
  • +3 more
  • (no location specified)
Jan 10, 2023

Prostate Cancer Trial in Boston, Brooklyn, New York (225Ac-J591, Pembrolizumab, Androgen receptor pathway inhibitor)

Recruiting
  • Prostate Cancer
  • Boston, Massachusetts
  • +3 more
Sep 20, 2021

Solid Tumor, Androgen Receptor Gene Overexpression Trial in Darlinghurst (SEVI-D (Seviteronel in combination with dexamthasone))

Terminated
  • Solid Tumor
  • Androgen Receptor Gene Overexpression
  • SEVI-D (Seviteronel in combination with dexamthasone)
  • Darlinghurst, New South Wales, Australia
    St Vincent's Hospital
Mar 2, 2021

Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7 Trial in Houston (procedure, drug,

Recruiting
  • Invasive Breast Carcinoma
  • +11 more
  • Axillary Lymph Node Dissection
  • +5 more
  • Houston, Texas
  • +1 more
Mar 10, 2022

Prostatic Tumors Trial in Worldwide (EPI-7386, Abiraterone Acetate, Prednisone or Prednisolone)

Suspended
  • Prostatic Neoplasms
  • Towson, Maryland
  • +3 more
Nov 3, 2022

Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen

Recruiting
  • Castration-Resistant Prostate Carcinoma
  • +7 more
  • Biopsy
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

Small Cell Neuroendocrine Carcinoma, Prostate Cancer, Small Cell Carcinoma Trial in San Francisco (Apalutamide, Cetrelimab)

Recruiting
  • Small Cell Neuroendocrine Carcinoma
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Mar 21, 2022

Advanced Prostate Cancer Trial in Baltimore (Pelvic DCFPyL PET-MRI fusion or PET/MRI)

Recruiting
  • Advanced Prostate Cancer
  • Pelvic DCFPyL PET-MRI fusion or PET/MRI
  • Baltimore, Maryland
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mar 22, 2022

Breast Tumors Trial in Nagoya, Kashiwa, Chuo-ku (ARV-471)

Not yet recruiting
  • Breast Neoplasms
  • Nagoya, Aichi, Japan
  • +2 more
Aug 12, 2022

Triple Negative Breast Cancer Trial (Seviteronel-D (Seivteronel in combination with dexamethasone), Docetaxel)

Not yet recruiting
  • Triple Negative Breast Cancer
  • Seviteronel-D (Seivteronel in combination with dexamethasone)
  • Docetaxel
  • (no location specified)
Sep 21, 2021

Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer Trial in United States (VERU-111,

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Androgen Resistant Prostatic Cancer
  • Anchorage, Alaska
  • +43 more
Jan 3, 2023